Table 2. Genes hosting variants with potential risk of sporadic DCM in the DCM cohort being studied.
Gene | Prevalencea of variants with risk of sporadic DCM | P valuec | Prevalencea of variants | Number of variants with risk of sporadic DCM | P valued | Number of total variants |
---|---|---|---|---|---|---|
MYBPC3 | 9 (13.6%)b | 0.000* | 11 | 6 | 0.010* | 7 |
SCN5A | 9 (13.6%) | 0.000* | 36 | 7 | 0.002* | 10 |
MYH7 | 8 (12.1%) | 0.001* | 8 | 8 | 0.001* | 8 |
MYPN | 6 (9.0%) | 0.011* | 142 | 4 | 0.140 | 10 |
LDB3 | 5 (7.6%) | 0.039* | 14 | 5 | 0.034* | 8 |
RBM20 | 4 (6.1%) | 0.114 | 135 | 4 | 0.140 | 9 |
LAMA4 | 4 (6.1%) | 0.114 | 236 | 3 | 0.261 | 10 |
SGCD | 3 (4.5%) | 0.277 | 3 | 3 | 0.261 | 3 |
ACTN2 | 2 (3.0%) | 0.546 | 8 | 2 | 0.528 | 3 |
TNNT2 | 2 (3.0%) | 0.546 | 6 | 1 | 0.830 | 2 |
MYH6 | 1 (1.5%) | 0.840 | 34 | 1 | 0.830 | 2 |
ABCC9 | 1 (1.5%) | 0.840 | 2 | 1 | 0.830 | 7 |
DES | 1 (1.5%) | 0.840 | 1 | 1 | 0.830 | 1 |
LMNA | 1 (1.5%) | 0.840 | 1 | 1 | 0.830 | 1 |
TPM1 | 1 (1.5%) | 0.840 | 1 | 1 | 0.830 | 1 |
TAZ | 1 (1.5%) | 0.840 | 1 | 1 | 0.830 | 1 |
VCL | 0 (0%) | 1.000 | 2 | 0 | 1.000 | 2 |
ACTC1 | 0 (0%) | 0 | 0 | 0 | ||
PLN | 0 (0%) | 0 | 0 | 0 | ||
PSEN1 | 0 (0%) | 0 | 0 | 0 | ||
PSEN2 | 0 (0%) | 0 | 0 | 0 | ||
TCAP | 0 (0%) | 0 | 0 | 0 | ||
TMPO | 0 (0%) | 0 | 0 | 0 | ||
TNNI3 | 0 (0%) | 0 | 0 | 0 |
a, prevalence was designated as the sum of patients carrying a variant (either homozygous or heterozygous) in each gene. When prevalence was calculated, variants co-occurring in a gene were counted separately. Likewise, variants co-occurring in a patient were also counted separately. b, prevalence in this column was also expressed as a percentage of the total patients in the DCM cohort. c,d, P values were computed using Poisson distribution as described in the Methods section. The means of the fitted Poisson distribution (λ) were 0.97 and 0.95, respectively. Only those genes that contained nonsynonymous variants were included in the computation. *, P<0.05.